Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068390 | 1.00 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13452269 | 1.00 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29952701 | 1.00 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5021152 | 1.00 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15382522 | 0.88 | CASP3 (0.55) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15929330 | 0.87 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14581384 | 0.87 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29445597 | 0.87 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL2625076 | 0.86 | KMT2A (0.58) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31453048 | 0.86 | CASP3 (0.53) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112386707-B | Tumor targeting polypeptide drug conjugate and preparation method thereof | 辽宁医学诊疗科技研发中心有限公司 | 2023-08-11 | — | — | CN | claimed |
| US-20260109743-A1 | PYY3-36 Analog and Use Thereof in Treating Disease | SUN TAO (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260098071-A1 | GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases | SUN TAO (CN) | 2026-04-09 | — | — | US | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| WO-2025229308-A1 | CONJUGATE FOR TREATING REPEAT EXPANSION DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| EP-4590423-A1 | METHODS AND PLATFORM FOR CHEMICAL SYNTHESIS | The University Court Of The University Of Glasgow (GB) | 2025-07-30 | — | — | EP | disclosed |
| US-20250186360-A1 | LIQUID-LIQUID PHASE SEPARATION (LLPS)-BASED COMPARTMENTS COMPRISING A SHORT PEPTIDE AND AN ANIONIC POLYMER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2025-06-12 | — | — | US | disclosed |
| EP-4532513-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011047215-A1 | IMPROVED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100286024-A1 | Insulinotropic compounds and uses thereof | ACTIVOTEC SPP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100168443-A1 | Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-07-01 | — | — | US | disclosed |
| EP-1943275-B1 | INSULINOTROPIC COMPOUNDS AND USES THEREOF | ACTIVOTEC SPP LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | CASP3 4704/4885KMT2A 995/4885EPHX2 3556/4885 |
| US-20100286024-A1 | Insulinotropic compounds and uses thereof | GLP1R, GPR119, IAPP | CASP3 2297/4885KMT2A 3871/4885EPHX2 2576/4885 |
| US-20260109743-A1 | PYY3-36 Analog and Use Thereof in Treating Disease | NPY1R, NPY4R, NPY2R | CASP3 2490/4885KMT2A 1512/4885EPHX2 3466/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CASP3 1026/4885KMT2A 4189/4885EPHX2 3191/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CASP3 1026/4885KMT2A 4189/4885EPHX2 3191/4885 |
| US-20260098071-A1 | GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases | GLP1R, GPR119, HTR1F | CASP3 2963/4885KMT2A 766/4885EPHX2 2628/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CASP3 1082/4885KMT2A 1569/4885EPHX2 4321/4885 |
| US-20100168443-A1 | Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use | PARG, POLH, PHOSPHO1 | CASP3 3633/4885KMT2A 1221/4885EPHX2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.